TEVA Overview
Upcoming Projects (TEVA)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (TEVA)
-
A Third Look at the Updated data from the phase 2b RELIEVE UCCD study of an anti-TL1A antibody (TEV-48574 aka duvakitug) in ulcerative colitis and Crohn’s disease.
Tickers: SNY, TEVA
Executed On: Mar 24, 2025 at 03:15 PM EDT -
A Second Look at the Updated data from the phase 2b RELIEVE UCCD study of an anti-TL1A antibody (TEV-48574 aka duvakitug) in ulcerative colitis and Crohn’s disease.
Tickers: SNY, TEVA
Executed On: Mar 18, 2025 at 09:00 AM EDT -
Updated data from the phase 2b RELIEVE UCCD study of an anti-TL1A antibody (TEV-48574 aka duvakitug) in ulcerative colitis and Crohn’s disease.
Tickers: SNY, TEVA
Executed On: Mar 11, 2025 at 04:30 PM EDT -
A Third Opinion: Delving into the recent data from the Phase 3 SPACE clinical trial of AJOVY (fremanezumab) in pediatric patients
Ticker: TEVA
Executed On: Feb 06, 2025 at 10:00 AM EST -
A Third Look: Discussing the publicly results from the phase 2b RELIEVE UCCD study of an anti-TL1A antibody (TEV-48574 aka duvakitug) in ulcerative colitis and Crohn’s disease.
Tickers: SNY, TEVA
Executed On: Jan 22, 2025 at 05:15 PM EST -
A Second Look: Discussing the publicly results from the phase 2b RELIEVE UCCD study of an anti-TL1A antibody (TEV-48574 aka duvakitug) in ulcerative colitis and Crohn’s disease.
Tickers: SNY, TEVA
Executed On: Jan 15, 2025 at 12:45 PM EST -
Discussing the publicly results from the phase 2b RELIEVE UCCD study of an anti-TL1A antibody (TEV-48574 aka duvakitug) in ulcerative colitis and Crohn’s disease.
Tickers: TEVA, SNY
Executed On: Jan 14, 2025 at 03:30 PM EST -
A Second Opinion: Delving into the recent data from the Phase 3 SPACE clinical trial of AJOVY (fremanezumab) in pediatric patients
Ticker: TEVA
Executed On: Dec 18, 2024 at 03:00 PM EST -
Delving into the recent data from the Phase 3 SPACE clinical trial of AJOVY (fremanezumab) in pediatric patients
Ticker: TEVA
Executed On: Dec 17, 2024 at 01:30 PM EST -
Third View: Discussing Teva's Recent Phase 3 Data for TEV-‘749 (olanzapine) as a Once-Monthly Injectable for Adult Patients Diagnosed with Schizophrenia.
Ticker: TEVA
Executed On: Oct 29, 2024 at 10:30 AM EDT -
Second View: Discussing Teva's Recent Phase 3 Data for TEV-‘749 (olanzapine) as a Once-Monthly Injectable for Adult Patients Diagnosed with Schizophrenia.
Ticker: TEVA
Executed On: Oct 24, 2024 at 04:00 PM EDT -
Discussing Teva's Recent Phase 3 Data for TEV-‘749 (olanzapine) as a Once-Monthly Injectable for Adult Patients Diagnosed with Schizophrenia.
Ticker: TEVA
Executed On: Oct 17, 2024 at 10:00 AM EDT -
A Third Look: Discussing the phase 3 SOLARIS clinical trial data on TEV-‘749 (olanzapine) in patients with Schizophrenia
Ticker: TEVA
Executed On: Jun 06, 2024 at 03:30 PM EDT -
A Second Look: Discussing the phase 3 SOLARIS clinical trial data on TEV-‘749 (olanzapine) in patients with Schizophrenia
Ticker: TEVA
Executed On: May 16, 2024 at 12:30 PM EDT -
Discussing the phase 3 SOLARIS clinical trial data on TEV-‘749 (olanzapine) in patients with Schizophrenia
Ticker: TEVA
Executed On: May 15, 2024 at 02:00 PM EDT -
A Second Look: Discussing the current state of ADHD medication shortages.
Ticker: TEVA
Executed On: Jan 10, 2024 at 02:00 PM EST -
Discussing the current state of ADHD medication shortages.
Ticker: TEVA
Executed On: Jan 09, 2024 at 10:00 AM EST
Upcoming & Overdue Catalysts (TEVA)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (TEVA)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
